Influence of graft composition in patients with hematological malignancies undergoing ATG-based haploidentical stem cell transplantation

被引:1
|
作者
Zhang, Ran [1 ]
Lu, Xuan [2 ]
Tang, Liang V. [2 ]
Wang, Huafang [2 ]
Yan, Han [2 ]
You, Yong [2 ]
Zhong, Zhaodong [2 ]
Shi, Wei [2 ]
Xia, Linghui [2 ]
机构
[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Hematol, Zhengzhou, Peoples R China
[2] Huazhong Univ Sci & Technol, Union Hosp, Inst Hematol, Tongji Med Coll, Wuhan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
haploidentical hematopoietic stem cell transplantation; graft composition; G-CSF-mobilized BM cells; G-CSF-mobilized PBSCs; total nucleated cells; MOBILIZED PERIPHERAL-BLOOD; PRIMED BONE-MARROW; POSTTRANSPLANT CYCLOPHOSPHAMIDE; CONDITIONING REGIMEN; LEUKEMIA; OUTCOMES; SURVIVAL;
D O I
10.3389/fimmu.2022.993419
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To determine the influence of graft composition in haplo-HSCT, we summarized the long-term consequences of 251 consecutive transplantations from haploidentical donors. For donor-recipient HLA3/6-matched setting, 125 cases used G-CSF-mobilized BM and PBSCs mixtures, while 126 cases only used G-CSF-mobilized PBSCs in HLA4/6-matched transplantation. On the one hand, we wanted to explore the effect of harvests (CD34+ cells and TNCs dosages) on transplantation outcome in the context of haplo-HSCT no matter HLA4/6 or HLA3/6-matched setting. On the other hand, for patients using G-CSF-mobilized BM and PBSCs combination in HLA3/6-matched setting, we attempted to analyze whether TNCs or CD34+ cells from G-CSF-mobilized BM or G-CSF-mobilized PBSCs play the most paramount role on transplantation prognosis. Collectively, patients with hematologic malignancies receiving G-CSF-primed BM and PBSCs harvests had comparable consequences with patients only receiving G-CSF-mobilized PBSCs. Moreover, when divided all patients averagely according to the total amount of transfused nucleated cells, 3-year TRM of the intermediate group (13.06-18.05x10(8)/kg) was only 4.9%, which was remarkably reduced when compared to lower and higher groups with corresponding values 18.3%, 19.6% (P=0.026). The 3-year probabilities of OS and DFS of this intermediate group were 72.6% and 66.5%, which were slightly improved than the lower and higher groups. Most importantly, these data suggest that the transfused nucleated cells from G-CSF-primed BM above than 5.20x10(8)/kg could achieve remarkably lower TRM in haplo-HSCT receiving G-CSF-mobilized BM and PBSCs harvests. These encouraging results suggested that we could improve the efficacy of haplo-HSCT by adjusting the component and relative ratio of transfused graft cells. Nevertheless, the above findings should be confirmed in a randomized prospective comparative research with adequate follow-up.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Improved survival in older patients with myeloid malignancies undergoing haploidentical peripheral blood stem cell transplantation with low-dose anti-thymocyte globin (ATG)/post-cyclophosphamide (PTCy)-based regimen for graft-versus-host disease prophylaxis
    Jia, Yannan
    Xia, Xinxin
    Yang, Jun
    Cai, Yu
    Tong, Yin
    Qiu, Huiying
    Huang, Chongmei
    Zhou, Kun
    Zhang, Ying
    Shen, Chang
    Wan, Liping
    Song, Xianmin
    ANNALS OF HEMATOLOGY, 2025, : 1857 - 1866
  • [12] Outcomes of Patients with Myeloid Malignancies and Cardiovascular Disease Undergoing Allogeneic Stem Cell Transplantation
    Sanchez-Petitto, Gabriela
    Goloubeva, Olga
    Childress, James
    Iqbal, Tahreem
    Masur, Jack
    An, Max
    Muhammad, Safwan
    Lawson, Justin
    Li, Grace
    Barr, Brian
    Emadi, Ashkan
    Duong, Vu H.
    Hardy, Nancy M.
    Rapoport, Aaron P.
    Baer, Maria R.
    Niyongere, Sandrine
    Yared, Jean A.
    ACTA HAEMATOLOGICA, 2024,
  • [13] Reduced intensity conditioning regimen of fludarabine, busulfan, ATG based haploidentical stem cell transplantation for older or unfit patients
    Pan, Mingyue
    Wu, Yibo
    Yang, Luxin
    Zhu, Panpan
    Shi, Jimin
    Lai, Xiaoyu
    Liu, Lizhen
    Zhao, Yanmin
    Yu, Jian
    Huang, He
    Luo, Yi
    ANNALS OF HEMATOLOGY, 2024, 103 (08) : 3105 - 3119
  • [14] Second haploidentical stem cell transplantation for primary graft failure
    Giammarco, Sabrina
    Raiola, Anna Maria
    Di Grazia, Carmen
    Bregante, Stefania
    Gualandi, Francesca
    Varaldo, Riccardo
    Chiusolo, Patrizia
    Sora, Federica
    Sica, Simona
    Laurenti, Luca
    Metafuni, Elisabetta
    Innocenti, Idanna
    Autore, Francesco
    Murgia, Barbara
    Bacigalupo, Andrea
    Angelucci, Emanuele
    BONE MARROW TRANSPLANTATION, 2021, 56 (06) : 1291 - 1296
  • [15] Comparison of the clinical outcomes between NIMA-mismatched and NIPA-mismatched haploidentical hematopoietic stem cell transplantation for patients with hematological malignancies
    Tang, Fei-Fei
    Zhao, Xiang-Yu
    Huo, Ming-Rui
    Chang, Ying-Jun
    Han, Wei
    Chen, Yu-Hong
    Yan, Chen-Hua
    Xu, Lan-Ping
    Zhang, Xiao-Hui
    Huang, Xiao-Jun
    Wang, Yu
    BONE MARROW TRANSPLANTATION, 2021, 56 (11) : 2723 - 2731
  • [16] Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies
    Alfaro Moya, Tommy
    Salas, Maria Queralt
    Santos Carreira, Abel
    Atenafu, Eshetu G.
    Law, Arjun Datt
    Lam, Wilson
    Pasic, Ivan
    Kim, Dennis
    Michelis, Fotios V.
    Novitzky Basso, Igor
    Gerbitz, Armin
    Lipton, Jeffrey Howard
    Kumar, Rajat
    Mattsson, Jonas
    Viswabandya, Auro
    BONE MARROW TRANSPLANTATION, 2024, 59 (04) : 534 - 540
  • [17] Reduced post-transplant cyclophosphamide doses in haploidentical hematopoietic cell transplantation for elderly patients with hematological malignancies
    Dulery, Remy
    Goudet, Claire
    Mannina, Daniele
    Bianchessi, Antonio
    Granata, Angela
    Harbi, Samia
    Maisano, Valerio
    Chabannon, Christian
    Malard, Florent
    Brissot, Eolia
    Sestili, Simona
    Banet, Anne
    van de Wyngaert, Zoe
    Belhocine, Ramdane
    Ederhy, Stephane
    Castagna, Luca
    Bramanti, Stefania
    Blaise, Didier
    Mohty, Mohamad
    Fuerst, Sabine
    Devillier, Raynier
    BONE MARROW TRANSPLANTATION, 2023, 58 (04) : 386 - 392
  • [18] Haploidentical Stem Cell Transplantation for Hematological Disorders: Real- World Experience from India
    Mehta, Pallavi
    Khushoo, Vishvdeep
    SOUTH ASIAN JOURNAL OF CANCER, 2023,
  • [19] Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies
    Li, Hua
    Li, Xiaofan
    Chen, Yiling
    Li, Duihong
    Chen, Xianling
    Zhu, Zhijuan
    Wang, Yiting
    Huang, Jiafu
    Chen, Ping
    Chen, Yuanzhong
    Li, Nainong
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [20] Antithymocyte globulin plus post-transplant cyclophosphamide combination as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation for hematological malignancies
    Chen, Tzu-Ting
    Lin, Ching-Chan
    Lo, Wen-Jyi
    Hsieh, Ching-Yun
    Lien, Ming-Yu
    Lin, Che-Hung
    Lin, Chen-Yuan
    Bai, Li-Yuan
    Chiu, Chang-Fang
    Yeh, Su-Peng
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (04) : 525 - 533